NOTE: this monograph does NOT apply to Hyoscine Hydrobromide.

1 vial

$1.91

Buscopan, Gastro-Soothe

  • Gastrointestinal tract spasm

IV:
20mg in 1ml (solution)
Room temperature. Protect from light.
Dilute required dose to 10ml with normal saline. Inject slowly over 3-5 minutes.
Compatible with the following IV fluids:
Normal saline 5% Glucose Glucose and sodium chloride
May be given into the side arm when the above IV fluids are being infused.

IM or SC:
Inject undiluted into a large muscle mass or subcutaneously

PO:
Buscopan 10mg (white)
Gastro-Soothe 10mg (white)


ADULT DOSE

IV, IM, SC, PO:
20-40mg 6-8 hourly

PAEDIATRIC DOSE

IV
0.5mg/kg 6-8 hourly IV

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function

Buscopan exerts a spasmolytic action on the smooth muscle of the gastrointestinal, biliary and urinary tracts. As a quaternary ammonium derivative, hyoscine-N-butylbromide does not enter the central nervous system. Therefore, anticholinergic side effects at the central nervous system do not occur. Peripheral anticholinergic effects result from a ganglion-blocking action within the visceral wall as well as from anti-muscarinic activity.

CONTRAINDICATIONS:

  • Myasthenia gravis

  • Mechanical gastrointestinal tract obstruction


WARNINGS
Tachycardia:
Hyoscine butylbromide may cause marked tachycardia
Urinary retention:
Hyoscine butylbromide may precipitate urinary retention

PRECAUTIONS
General
Hyoscine butylbromide should not be given by intramuscular injection to patients being treated with anticoagulant drugs since intramuscular haematoma may occur. In these patients, the subcutaneous or intravenous routes may be used

Laboratory Tests
No tests in addition to routine ICU tests are required

Drug/Laboratory Test Interactions
None known

The anticholinergic effect of drugs such as tricyclic antidepressants, antihistamines, quinidine, amantadine, disopyramide and other anticholinergics (e.g. tiotropium, ipratropium) may be intensified by Hyoscine-N-butylbromide.
Concomitant treatment with dopamine antagonists such as metoclopramide may result in diminution of the effects of both drugs on the gastrointestinal tract.
The tachycardic effects of beta-adrenergic agents may be enhanced by Hyoscine-N-butylbromide

Body as a Whole Anaphylactic shock, anaphylactoid reactions and other hypersensitivity, skin reactions

Cardiovascular Tachycardia, hypotension, dizziness, flushing
Respiratory
Dyspnoea
Gastrointestinal Dry mouth

Renal and urinary disorders Urinary retention

[an error occurred while processing this directive]